IMAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IMAX Corp is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive financial growth in revenue and gross margin, the recent decline in net income and EPS, coupled with insider selling and the CEO's medical leave, raises concerns about stability. The lack of strong trading signals and mixed analyst ratings further support a hold decision.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 72.129, which is neutral but approaching overbought levels. Moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R2: 40.691), which may limit immediate upside potential.
Strong Q4 revenue growth (up 35.11% YoY) and gross margin improvement (up 10.77% YoY). Analysts from Benchmark and B. Riley have raised price targets and maintain buy ratings, citing international expansion and robust system installs.
CEO's medical leave impacting market confidence. Insider selling has increased significantly (486.11% in the last month). Net income and EPS have dropped sharply (-87.99% and -90.00% YoY, respectively). Mixed analyst ratings with some maintaining neutral positions. Stock trend analysis indicates potential short-term downside (-1.63% in the next week, -4.43% in the next month).
In Q4 2025, revenue increased by 35.11% YoY to $125.2M, driven by a strong box office and system installs. However, net income dropped by 87.99% YoY to $637K, and EPS fell by 90.00% YoY to $0.01. Gross margin improved to 55.96%, up 10.77% YoY.
Analyst sentiment is mixed. Benchmark, B. Riley, and JPMorgan have raised price targets and maintain buy/overweight ratings, citing strong financial performance and strategic growth. However, Goldman Sachs has a neutral rating and recently lowered its price target.
